Published in Neurobiol Aging on March 01, 2006
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. JAMA Neurol (2014) 2.28
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia. Proc Natl Acad Sci U S A (2009) 1.49
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations. J Alzheimers Dis (2013) 0.83
The pathological roles of ganglioside metabolism in Alzheimer's disease: effects of gangliosides on neurogenesis. Int J Alzheimers Dis (2011) 0.83
Presenilin/gamma-Secretase and Inflammation. Front Aging Neurosci (2010) 0.79
Clinical, biological, and imaging features of monogenic Alzheimer's Disease. Biomed Res Int (2013) 0.77
Elevation in sphingomyelin synthase activity is associated with increases in amyloid-beta peptide generation. PLoS One (2013) 0.76
The effects of chronic smoking on the pathology of alcohol-related brain damage. Alcohol (2016) 0.75
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
Life events, first depression onset and the serotonin transporter gene. Br J Psychiatry (2006) 3.32
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
The pathological basis of semantic dementia. Brain (2005) 2.96
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet (2011) 2.71
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol (2008) 2.34
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Neuropathologic correlates of white matter hyperintensities. Neurology (2008) 2.29
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol (2005) 2.14
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Ligand-gated ion channels: mechanisms underlying ion selectivity. Prog Biophys Mol Biol (2004) 1.96
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry (2011) 1.79
Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol (2008) 1.74
In vivo identification of human cortical areas using high-resolution MRI: an approach to cerebral structure-function correlation. Proc Natl Acad Sci U S A (2003) 1.72
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol (2004) 1.61
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov Disord (2012) 1.56
The brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorder. Biol Psychiatry (2013) 1.54
Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol (2006) 1.47
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Argyrophilic staining of nucleolar organizer region count and morphometry in benign and malignant melanocytic lesions. Am J Dermatopathol (2003) 1.44
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology (2012) 1.44
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov Disord (2013) 1.39
Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord (2007) 1.39
Cation-selective mutations in the M2 domain of the inhibitory glycine receptor channel reveal determinants of ion-charge selectivity. J Gen Physiol (2002) 1.30
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol (2008) 1.26
Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry (2010) 1.26
Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. Eur J Hum Genet (2010) 1.26
Implications of genetic risk information in families with a high density of bipolar disorder: an exploratory study. Soc Sci Med (2005) 1.25
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A (2010) 1.24
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol (2010) 1.24
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Attitudes towards childbearing, causal attributions for bipolar disorder and psychological distress: a study of families with multiple cases of bipolar disorder. Psychol Med (2007) 1.20
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem (2002) 1.19
Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (2004) 1.19
The contribution of proline 250 (P-2') to pore diameter and ion selectivity in the human glycine receptor channel. Neurosci Lett (2003) 1.18
α-Synucleinopathy phenotypes. Parkinsonism Relat Disord (2014) 1.16
Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). Hum Mol Genet (2002) 1.16
Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology (2013) 1.16
Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression. J Affect Disord (2006) 1.13
Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2001) 1.12
Subcortical vascular disease and functional decline: a 6-year predictor study. J Am Geriatr Soc (2002) 1.11
Familial idiopathic basal ganglia calcification (Fahr's disease) without neurological, cognitive and psychiatric symptoms is not linked to the IBGC1 locus on chromosome 14q. Hum Genet (2001) 1.11
Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol (2003) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Distinct physiological mechanisms underlie altered glycinergic synaptic transmission in the murine mutants spastic, spasmodic, and oscillator. J Neurosci (2006) 1.09
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord (2002) 1.09
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08
'Negativity bias' in risk for depression and anxiety: brain-body fear circuitry correlates, 5-HTT-LPR and early life stress. Neuroimage (2009) 1.08
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain (2003) 1.06
Role of charged residues in coupling ligand binding and channel activation in the extracellular domain of the glycine receptor. J Biol Chem (2003) 1.06
Attitudes to genetic testing in families with multiple cases of bipolar disorder. Genet Test (2008) 1.06
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
Issues concerning feedback about genetic testing and risk of depression. Br J Psychiatry (2009) 1.04
Human alcohol-related neuropathology. Acta Neuropathol (2013) 1.04
Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol (2012) 1.03
Gating mechanisms in Cys-loop receptors. Eur Biophys J (2009) 1.03
Mechanisms of channel gating of the ligand-gated ion channel superfamily inferred from protein structure. Exp Physiol (2004) 1.03
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci (2005) 1.02
Kinetic determinants of agonist action at the recombinant human glycine receptor. J Physiol (2003) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
COMT Val(108/158)Met polymorphism effects on emotional brain function and negativity bias. Neuroimage (2010) 1.00
Single channel analysis of conductance and rectification in cation-selective, mutant glycine receptor channels. J Gen Physiol (2002) 0.99
Understanding the pathogenesis of Alzheimer's disease: will RNA-Seq realize the promise of transcriptomics? J Neurochem (2011) 0.98
Early life stress combined with serotonin 3A receptor and brain-derived neurotrophic factor valine 66 to methionine genotypes impacts emotional brain and arousal correlates of risk for depression. Biol Psychiatry (2010) 0.98